Cariprazine and Omaveloxolone: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 16, 2026 · Source data updated Jul 16, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Omaveloxolone
Cariprazine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Omaveloxolone (Skyclarys) can speed up an enzyme in your liver called CYP3A4. That same enzyme handles cariprazine (Vraylar), both building it into its active form and clearing it out of your body. Because the enzyme does two opposite jobs with cariprazine, it's genuinely hard to predict whether the levels go up or down when these are taken together.
The good news is this concern comes from how the drugs work on paper, not from reported problems. Your care team can handle it by watching how you're doing and adjusting if needed. Don't stop or change either medicine on your own. Just let your pharmacist or doctor know you take both.
Mechanism: Omaveloxolone is a CYP3A4 inducer; cariprazine is a CYP3A4 substrate whose active metabolites (desmethyl- and didesmethyl-cariprazine) are both formed and eliminated via CYP3A4.
- Direction/magnitude: Net effect on total active-moiety exposure is unpredictable and has not been formally studied.
- Evidence: Theoretical; severity major; onset unspecified.
- Management: Concomitant use is not recommended. If unavoidable, monitor for loss of efficacy (psychiatric decompensation) and for adverse effects; dose may need individualization by the care team. Consider an alternative agent not affected by CYP3A4 induction.
What happens
Effects on the cariprazine exposure has not been evaluated and the net effect is unclear
Interaction Deep Dive
The joint use of cariprazine (which is a substrate of CYP3A4) with a CYP3A4 inducer is advised against. The formation as well as the elimination of cariprazine's active metabolites depends on CYP3A4. How CYP3A4 inducers influence cariprazine exposure has not been studied, so the overall outcome remains uncertain1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of cariprazine
How to manage this interaction
How your care team typically handles this:
- Combining a CYP3A4 inducer like omaveloxolone with cariprazine is generally not recommended, so your prescriber may consider whether a different medication makes more sense for you.
- If you do take both, your team may monitor you more closely, watching both for the return of symptoms and for side effects, and your dose may be adjusted and individualized.
What you should do: Keep taking both exactly as prescribed unless told otherwise, and let your pharmacist or prescriber know you're on this combination so they can decide the best plan.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Cariprazine and Omaveloxolone together?
Combining omaveloxolone (a CYP3A4 inducer) with cariprazine can unpredictably change cariprazine's active drug levels, so this pairing is generally not recommended. Tell your pharmacist or doctor you take both so they can monitor you or choose an alternative. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Cariprazine and Omaveloxolone interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Cariprazine and Omaveloxolone interaction managed?
How your care team typically handles this: Combining a CYP3A4 inducer like omaveloxolone with cariprazine is generally not recommended, so your prescriber may consider whether a different medication makes more sense for you. If you do take both, your team may monitor you more closely, watching both for the return of symptoms and for side effects, and your dose may be adjusted and individualized. W… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Cariprazine or Omaveloxolone need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: VRAYLAR(R) oral capsules, cariprazine oral capsules. AbbVie Inc. (per FDA), North Chicago, IL, 2024. DailyMed
Keep reading about Omaveloxolone
Keep reading about Cariprazine
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist